Lourd Capital’s GSK GSK Stock Holding History

Lourd Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-8,926	Closed	-$426K	–	191
2018 Q4	$426K	Sell	8,926 -609	-6%	-$30K	0.03%	135
2018 Q3	$479K	Buy	9,535 +518	+6%	+$26.3K	0.03%	135
2018 Q2	$454K	Buy	9,017 +46	+0.5%	+$2.32K	0.06%	85
2018 Q1	$438K	Sell	8,971 -5,755	-39%	-$268K	0.06%	95
2017 Q4	$653K	Buy	+14,726	New	+$680K	0.04%	120

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Lourd Capital's GSK Position: Q1 2019 in Review

Lourd Capital sold out of GSK (GSK) in Q1 2019, closing a stake of 8,926 shares — an estimated $426K sold.

Lourd Capital first reported a position in GSK in Q4 2017 and held it in 5 quarters. The position peaked at $653K in Q4 2017. 847 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

Lourd Capital reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
Lourd Capital sold 8,926 GSK shares in Q1 2019, an estimated $426K.
Lourd Capital first reported a position in GSK in Q4 2017 and held it in 5 quarters.
Lourd Capital's GSK position peaked at $653K in Q4 2017.
847 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Lourd Capital's 13F filing for Q1 2019, filed 16 Apr 2019.